Erlotinib Tablets 150mg

Erlotinib Tablets 150mg Specification

Origin of Medicine
India

Packaging Type
Blister Pack or Box

Salt Composition
Erlotinib Hydrochloride 150mg

Brand Name
Specification varies (common brands: Erlonat, Erlocip, etc.)

Dosage Form
Solid Oral Tablet

Life Span
24 months from manufacturing date

Indication
Locally advanced or metastatic non-small cell lung cancer, metastatic pancreatic cancer

Pacakaging (Quantity Per Box)
30 tablets

Drug Type
Allopathic

Ingredients
Erlotinib Hydrochloride

Physical Form
Tablets

Function
Anti-cancer/Antineoplastic Agent, Epidermal Growth Factor Receptor (EGFR) Inhibitor

Recommended For
Non-Small Cell Lung Cancer, Pancreatic Cancer

Dosage
As prescribed by physician, commonly 150mg once daily

Dosage Guidelines
Take on an empty stomach, at least 1 hour before or 2 hours after eating, as directed by the physician

Suitable For
Adults

Quantity
30 Tablets per box

Storage Instructions
Store at room temperature, 20C to 25C (68F to 77F), away from moisture and light

Manufacturing Compliance
cGMP, WHO-GMP Certified

Regulatory Status
Rx - Prescription Only

Imprint
May include identifying number or logo according to manufacturer

Marketed By
Various pharmaceutical companies

Shape
Round

Country of Export
Available for export to multiple countries

Prescription Required
Yes

Route of Administration
Oral

Administration Frequency
Once daily

Side Effects
Rash, diarrhea, anorexia, fatigue, hepatic impairment

Color of Tablet
White to off-white

Therapeutic Class
Antineoplastic Agents, Tyrosine Kinase Inhibitors

Contraindications
Known hypersensitivity to Erlotinib or any excipients

Erlotinib Tablets 150mg Trade Information

Minimum Order Quantity
10 Pieces

Supply Ability
5000 Pieces Per Month

Delivery Time
7 Days

About Erlotinib Tablets 150mg

Packaging Size	30 Tablets
Strength	150 mg
Brand	Erlonat
Manufacturer	Natco
Form	Tablet
Medicine Type	Allopathic
Packaging Type	Bottle

Erlotinib Tablets is used in the treatment of non-small cell lung cancer and pancreatic cancer.

Key Features and Compliance

Erlotinib Tablets 150mg are produced under strict cGMP and WHO-GMP guidelines, ensuring high-quality standards for safety and efficacy. The tablets are round, white to off-white, and may feature an identifying code or logo depending on the manufacturer. Each box contains 30 tablets, supporting a month-long regimen under physician supervision. Packaging options include blister packs or boxes, with a shelf life of 24 months.

Therapeutic Applications and Benefits

These tablets act as epidermal growth factor receptor (EGFR) inhibitors, primarily indicated for adults diagnosed with advanced non-small cell lung cancer or metastatic pancreatic cancer. Erlotinib impedes cancer cell growth by blocking specific signaling pathways, potentially slowing disease progression and improving quality of life for eligible patients.

Usage and Administration Guidelines

Erlotinib Tablets are meant for oral intake, commonly at 150mg once daily, as directed by a healthcare provider. To maximize absorption and effectiveness, it is recommended to take the medication on an empty stomach-at least one hour before or two hours after eating. Storage should be at room temperature, in a dry place away from light.

FAQ's of Erlotinib Tablets 150mg:

Q: How should Erlotinib Tablets 150mg be taken for optimal effectiveness?

A: Erlotinib Tablets should be taken orally, once daily, on an empty stomach. It is advisable to take them at least one hour before or two hours after a meal, as directed by your physician, to enhance absorption and effectiveness.

Q: What conditions is Erlotinib 150mg commonly prescribed for?

A: This medication is mainly prescribed for adults with locally advanced or metastatic non-small cell lung cancer and metastatic pancreatic cancer, helping inhibit the growth of cancer cells.

Q: When should Erlotinib not be used?

A: Erlotinib should not be used in individuals with known hypersensitivity to Erlotinib or any of its excipients. Consult your healthcare provider if you have a history of allergic reactions to medications.

Q: Where are Erlotinib Tablets manufactured and can they be exported?

A: Erlotinib Tablets are manufactured in India at facilities compliant with cGMP and WHO-GMP standards. They are available for export to multiple countries, supporting global access to quality oncology medications.

Q: What side effects may occur with Erlotinib Tablets?

A: Common side effects include rash, diarrhea, anorexia, fatigue, and liver function impairment. Any persistent or severe symptoms should be reported to your healthcare professional promptly.

Q: What is the process for obtaining Erlotinib Tablets 150mg?

A: Erlotinib Tablets are prescription-only. A valid prescription from a licensed healthcare provider is required to purchase this medication from authorized pharmacies or exporters.

Q: What benefits can patients expect from Erlotinib treatment?

A: Erlotinib is designed to slow the progression of certain cancers by inhibiting cancer cell growth, potentially improving survival and quality of life for individuals with advanced lung or pancreatic cancer.